Skip to Main Content

A Study of Autologous Neo-Kidney Augment™ (NKA) in Type 2 Diabetics With Chronic Kidney Disease

Conditions

Diabetes Mellitus - Type 2 | Diseases of the Kidney & Urinary Tract

Phase II

What is the purpose of this trial?

Brief Summary:

The purpose of the present study is to compare the safety and efficacy of up to 2 injections of NKA given 3 to 6 months apart (maximum) in subjects who are randomized to receive their first treatment as soon as the NKA product is made available versus subjects who are randomized to undergo contemporaneous, standard-of-care treatment for CKD during the first 12 18 months prior to receiving up to 2 injections of NKA.

  • Trial with
    inRegen
  • Start Date
    06/10/2018
  • End Date
    12/30/2018
Trial Image

For more information about this study, contact:

Rodolfo Molina

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

  • Last Updated
    06/13/2018
  • Study HIC
    #2000021970